1. Home
  2. NKSH vs ANIK Comparison

NKSH vs ANIK Comparison

Compare NKSH & ANIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NKSH

National Bankshares Inc.

HOLD

Current Price

$35.21

Market Cap

233.8M

Sector

Finance

ML Signal

HOLD

Logo Anika Therapeutics Inc.

ANIK

Anika Therapeutics Inc.

HOLD

Current Price

$14.71

Market Cap

198.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NKSH
ANIK
Founded
1891
1983
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
233.8M
198.9M
IPO Year
1995
1996

Fundamental Metrics

Financial Performance
Metric
NKSH
ANIK
Price
$35.21
$14.71
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$17.00
AVG Volume (30 Days)
31.7K
72.8K
Earning Date
04-23-2026
04-29-2026
Dividend Yield
4.22%
N/A
EPS Growth
100.81
80.16
EPS
0.78
N/A
Revenue
$8,176,000.00
$112,819,000.00
Revenue This Year
N/A
$5.98
Revenue Next Year
N/A
$7.42
P/E Ratio
$45.01
N/A
Revenue Growth
9.39
N/A
52 Week Low
$24.74
$7.90
52 Week High
$40.00
$16.24

Technical Indicators

Market Signals
Indicator
NKSH
ANIK
Relative Strength Index (RSI) 44.08 47.12
Support Level $35.09 $13.95
Resistance Level $38.24 $15.01
Average True Range (ATR) 1.02 0.56
MACD -0.00 -0.04
Stochastic Oscillator 26.13 23.32

Price Performance

Historical Comparison
NKSH
ANIK

About NKSH National Bankshares Inc.

National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural loans, commercial real estate, construction loans for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary. The company earns its revenue from interest and fees on loans, non-interest income, and investments.

About ANIK Anika Therapeutics Inc.

Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.

Share on Social Networks: